sema + cagrilintide 1 CagriSema 2.4 mg / 2.4 mg FDA NDA filing; Novo Nordisk data on file. 2 Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered and semaglutide in adults with Cagrilintide–Semaglutide in Adults with Overweight

Avoid food that needs persistent chewing to breakdown

The loading phase (Weeks 14) uses twice-weekly dosing to establish tissue saturation, followed by a maintenance phase (Weeks 512) at once weekly [1]

Compounded semaglutide side effects The most common side effects of compounded semaglutide are: Nausea Abdominal discomfort Vomiting Diarrhea Constipation Rare and serious side effects of the medication include: Severe stomach problems Changes in vision (due to diabetic retinopathy) Hypersensitivity/allergic reaction Acute pancreatitis Gallbladder problems Hypoglycemia (low blood sugar levels) Increased risk of aspiration in anesthesia and sedation Mood and behavioral changes In rodents, semaglutide (the investigational product in clinical trials, which was later approved as Wegovy and Ozempic) increases the risk of thyroid cancers

Kennedy has publicly advocated for lifting restrictions on peptides and talked up their benefits

Its value is in what it adds when combined with GLP-1 agonism

Give patient information sheet appendix 1 GIVE ADVICE ON SICK DAY RULES and give STEROID EMERGENCY CARD ( For advice on how to safely withdraw long term steroids see patient information letter ) see page 5 GASTROPROTECTION: PPI (proton pump inhibitor) therapy should not be given routinely but should be considered for people at high risk of gastrointestinal bleeding or dyspepsia